20
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Engineering Protein Farnesyltransferase for Enzymatic Protein Labeling Applications

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Creating covalent protein conjugates is an active area of research due to the wide range of uses for protein conjugates spanning everything from biological studies to protein therapeutics. Protein Farnesyltransferase (PFTase) has been used for the creation of site-specific protein conjugates, and a number of PFTase substrates have been developed to facilitate that work. PFTase is an effective catalyst for protein modification because it transfers Farnesyl diphosphate (FPP) analogues to protein substrates on a cysteine four residues from the C-terminus. While much work has been done to synthesize various FPP analogues, there are few reports investigating how mutations in PFTase alter the kinetics with these unnatural analogues. Herein we examined how different mutations within the PFTase active site alter the kinetics of the PFTase reaction with a series of large FPP analogues. We found that mutating either a single tryptophan or tyrosine residue to alanine results in greatly improved catalytic parameters, particularly in k cat. Mutation of tryptophan 102β to alanine caused a 4-fold increase in k cat and a 10-fold decrease in K M for a benzaldehyde-containing FPP analogue resulting in an overall 40-fold increase in catalytic efficiency. Similarly, mutation of tyrosine 205β to alanine caused a 25-fold increase in k cat and a 10-fold decrease in K M for a coumarin-containing analogue leading to a 300-fold increase in catalytic efficiency. Smaller but significant changes in catalytic parameters were also obtained for cyclo-octene- and NBD-containing FPP analogues. The latter compound was used to create a fluorescently labeled form of Ciliary Neurotrophic Factor (CNTF), a protein of therapeutic importance. Additionally, computational modeling was performed to study how the large non-natural isoprenoid analogues can fit into the active sites enlarged via mutagenesis. Overall, these results demonstrate that PFTase can be improved via mutagenesis in ways that will be useful for protein engineering and the creation of site-specific protein conjugates.

          Related collections

          Most cited references42

          • Record: found
          • Abstract: found
          • Article: not found

          Tetrazine ligation: fast bioconjugation based on inverse-electron-demand Diels-Alder reactivity.

          Described is a bioorthogonal reaction that proceeds with unusually fast reaction rates without need for catalysis: the cycloaddition of s-tetrazine and trans-cyclooctene derivatives. The reactions tolerate a broad range of functionality and proceed in high yield in organic solvents, water, cell media, or cell lysate. The rate of the ligation between trans-cyclooctene and 3,6-di-(2-pyridyl)-s-tetrazine is very rapid (k2 2000 M-1 s-1). This fast reactivity enables protein modification at low concentration.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Targeting protein prenylation for cancer therapy.

            Protein farnesylation and geranylgeranylation, together referred to as prenylation, are lipid post-translational modifications that are required for the transforming activity of many oncogenic proteins, including some RAS family members. This observation prompted the development of inhibitors of farnesyltransferase (FT) and geranylgeranyl-transferase 1 (GGT1) as potential anticancer drugs. In this Review, we discuss the mechanisms by which FT and GGT1 inhibitors (FTIs and GGTIs, respectively) affect signal transduction pathways, cell cycle progression, proliferation and cell survival. In contrast to their preclinical efficacy, only a small subset of patients responds to FTIs. Identifying tumours that depend on farnesylation for survival remains a challenge, and strategies to overcome this are discussed. One GGTI has recently entered the clinic, and the safety and efficacy of GGTIs await results from clinical trials.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Targeting quantum dots to surface proteins in living cells with biotin ligase.

              Escherichia coli biotin ligase site-specifically biotinylates a lysine side chain within a 15-amino acid acceptor peptide (AP) sequence. We show that mammalian cell surface proteins tagged with AP can be biotinylated by biotin ligase added to the medium, while endogenous proteins remain unmodified. The biotin group then serves as a handle for targeting streptavidin-conjugated quantum dots (QDs). This labeling method helps to address the two major deficiencies of antibody-based labeling, which is currently the most common method for targeting QDs to cells: the size of the QD conjugate after antibody attachment and the instability of many antibody-antigen interactions. To demonstrate the versatility of our method, we targeted QDs to cell surface cyan fluorescent protein and epidermal growth factor receptor in HeLa cells and to alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors in neurons. Labeling requires only 2 min, is extremely specific for the AP-tagged protein, and is highly sensitive. We performed time-lapse imaging of single QDs bound to AMPA receptors in neurons, and we compared the trafficking of different AMPA receptor subunits by using two-color pulse-chase labeling.
                Bookmark

                Author and article information

                Journal
                Bioconjug Chem
                Bioconjug. Chem
                bc
                bcches
                Bioconjugate Chemistry
                American Chemical Society
                1043-1802
                1520-4812
                19 June 2015
                19 June 2014
                16 July 2014
                : 25
                : 7
                : 1203-1212
                Affiliations
                []Department of Chemistry, University of Minnesota , Minneapolis, Minnesota 55455, United States
                []Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota , St. Paul, Minnesota 55108, United States
                Author notes
                [* ]Tel: (+612) 624-0544. Fax: (+612) 626-7541. E-mail: diste001@ 123456umn.edu .
                Article
                10.1021/bc500240p
                4103756
                24946229
                0463bf3b-68c1-402c-be59-56bc1ba8fb82
                Copyright © 2014 American Chemical Society

                Terms of Use

                History
                : 14 November 2013
                : 17 June 2014
                Funding
                National Institutes of Health, United States
                Categories
                Article
                Custom metadata
                bc500240p
                bc-2014-00240p

                Biochemistry
                Biochemistry

                Comments

                Comment on this article